4/A - CITIUS ONCOLOGY, INC. (0001851484) (Issuer)

4/A - CITIUS ONCOLOGY, INC. (0001851484) (Issuer)

4/A - CITIUS ONCOLOGY, INC. (0001851484) (Issuer)

4/A - CITIUS ONCOLOGY, INC. (0001851484) (Issuer)

4/A - CITIUS ONCOLOGY, INC. (0001851484) (Issuer)

4/A - CITIUS ONCOLOGY, INC. (0001851484) (Issuer)

4/A - CITIUS ONCOLOGY, INC. (0001851484) (Issuer)

4/A - CITIUS ONCOLOGY, INC. (0001851484) (Issuer)

4/A - CITIUS ONCOLOGY, INC. (0001851484) (Issuer)

4/A - CITIUS ONCOLOGY, INC. (0001851484) (Issuer)

Maxim Group upgraded Citius Oncology from Hold to Buy and set a new price target of $6.00

Maxim Group initiated coverage of Citius Oncology with a rating of Buy and set a new price target of $3.00

8-K - CITIUS ONCOLOGY, INC. (0001851484) (Filer)

SCHEDULE 13G - CITIUS ONCOLOGY, INC. (0001851484) (Subject)

8-K - CITIUS ONCOLOGY, INC. (0001851484) (Filer)

8-K - CITIUS ONCOLOGY, INC. (0001851484) (Filer)

DEF 14A - CITIUS ONCOLOGY, INC. (0001851484) (Filer)

S-8 - CITIUS ONCOLOGY, INC. (0001851484) (Filer)

8-K - CITIUS ONCOLOGY, INC. (0001851484) (Filer)

SCHEDULE 13D/A - CITIUS ONCOLOGY, INC. (0001851484) (Subject)

424B3 - CITIUS ONCOLOGY, INC. (0001851484) (Filer)

8-K - CITIUS ONCOLOGY, INC. (0001851484) (Filer)

Partnership expands access to LYMPHIR for patients with cutaneous T-cell lymphoma across Turkey, Bahrain, Qatar, Oman, Kuwait, Saudi Arabia, and the UAE LYMPHIR international availability extends to 19 markets outside the U.S. CRANFORD, N.J., Dec. 4, 2025 /PRNewswire/ -- Citius Oncology, Inc. ("Citius Oncology") (NASDAQ:CTOR), the oncology-focused subsidiary of Citius Pharmaceuticals, Inc. ("Citius Pharma") (NASDAQ:CTXR), today announced that it has entered into an exclusive distribution agreement with Er-Kim İlaç Sanayi ve Ticaret A.Ş. ("Er-Kim"), a leading pharmaceutical distributor based in Turkey, for LYMPHIR (denileukin diftitox-cxdl), a novel IL-2 receptor-directed cytotoxin, approved

AUSTIN, Texas, Dec. 04, 2025 (GLOBE NEWSWIRE) -- BioMedWire Editorial Coverage: Chronic illnesses and rare disorders among older Americans represent a rapidly intensifying challenge for the U.S. healthcare system, with the National Institutes of Health estimating that more than 30 million people nationwide are living with a rare disease. Most of these conditions have no FDA-approved therapies, leaving older adults particularly at risk as age-related changes can mask or delay accurate diagnosis. This growing strain on care has heightened the need for novel treatments that address significant unmet medical needs. Soligenix Inc. (NASDAQ:SNGX) (Profile), a late-stage biopharmaceutical develope

LYMPHIR now available nationwide CRANFORD, N.J., Dec. 1, 2025 /PRNewswire/ -- Citius Oncology, Inc. ("Citius Oncology") (NASDAQ:CTOR), the oncology-focused subsidiary of Citius Pharmaceuticals, Inc. ("Citius Pharma") (NASDAQ:CTXR), today announced the commercial launch of LYMPHIR™ (denileukin diftitox-cxdl). LYMPHIR is a novel IL-2 receptor-directed fusion protein approved by the U.S. Food and Drug Administration (FDA) for the treatment of adult patients with relapsed or refractory (r/r) Stage I–III cutaneous T-cell lymphoma (CTCL) after at least one prior systemic therapy. "L

Citius Oncology's LYMPHIR™ exhibit will be located at Booth #265 LYMPHIR launch on track for Q4 2025 CRANFORD, N.J., Nov. 25, 2025 /PRNewswire/ -- Citius Oncology, Inc. ("Citius Oncology") (NASDAQ:CTOR), the oncology-focused subsidiary of Citius Pharmaceuticals, Inc. ("Citius Pharma") (NASDAQ:CTXR), today announced it will exhibit at the 67th American Society of Hematology (ASH) Annual Meeting & Exposition, taking place December 6–9, 2025, in Orlando, Florida. The Citius Oncology team will be located at Booth #265 in the ASH Exhibit Hall to discuss LYMPHIR (denileukin diftitox-cxdl), its novel IL-2 receptor-directed fusion protein approved by the U.S. Food and Drug Administration (FDA) for

Leading edge artificial intelligence and machine learning platform supports enhanced salesforce targeting and engagement for cutaneous T-cell lymphoma immunotherapy launch CRANFORD, N.J., Nov. 21, 2025 /PRNewswire/ -- Citius Oncology, Inc. ("Citius Oncology") (NASDAQ:CTOR), the oncology-focused subsidiary of Citius Pharmaceuticals, Inc. ("Citius Pharma") (NASDAQ:CTXR), a late-stage biopharmaceutical company developing and commercializing first-in-class critical care products, today announced a deeper collaboration with Verix, a leader in AI-powered commercial optimization technology for the life sciences sector. Citius Oncology's commercial team intends to further leverage Verix's innovative

McKesson joins leading distribution service providers as authorized U.S. distributor of LYMPHIR CRANFORD, N.J., Oct. 20, 2025 /PRNewswire/ -- Citius Oncology, Inc. ("Citius Oncology") (NASDAQ:CTOR), the oncology-focused subsidiary of Citius Pharmaceuticals, Inc. ("Citius Pharma") (NASDAQ:CTXR), today announced it has entered into a distribution services agreement with McKesson Corporation (NYSE:MCK), one of the largest pharmaceutical distributors and healthcare services companies in North America. Under the agreement, McKesson will serve as an authorized distributor of record for LYMPHIR (denileukin diftitox-cxdl), a novel immunotherapy approved by the U.S. Food and Drug Administration (FDA)

LD Micro Main Event XIX, October 19-21, 2025 2025 Maxim Growth Summit, October 22-23, 2025 The Think Equity Conference, October 30, 2025 CRANFORD, N.J., Oct. 17, 2025 /PRNewswire/ -- Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) and Citius Oncology, Inc. (NASDAQ:CTOR) today announced that management will be participating in three investor conferences in October 2025. Citius Pharmaceuticals (NASDAQ:CTXR) Event: LD Micro Main Event XIX Date: October 19-21, 2025 Location: Hotel Del Coronado, San Diego, California Event website: Conference registration  Event: Think Equity Conference Date: October 30, 2025 Location: Mandarin Oriental, New York Event website: Conference registration  Interes

EVERSANA to provide integrated commercialization services, enhancing launch readiness and market entry for differentiated Cutaneous T-cell Lymphoma therapy CRANFORD, N.J., Oct. 16, 2025 /PRNewswire/ -- Citius Oncology, Inc. ("Citius Oncology") (NASDAQ:CTOR), the oncology-focused subsidiary of Citius Pharmaceuticals, Inc. ("Citius Pharma") (NASDAQ:CTXR), today announced it has finalized an exclusive agreement with EVERSANA®, a leading provider of global commercialization services, to support the anticipated fourth quarter 2025 U.S. commercialization of LYMPHIR™ (denileukin diftitox-cxdl), Citius Oncology's FDA-approved therapy for relapsed or refractory cutaneous T-cell lymphoma (CTCL) follow

Equity Insider News Commentary Issued on behalf of GT Biopharma, Inc. VANCOUVER, BC, Oct. 8, 2025 /PRNewswire/ -- Ohio State researchers recently solved a critical mystery explaining why some cancer immunotherapies fail[1], while a University of Chicago team discovered a common supplement that supercharges immune cells against tumors[2]. These breakthroughs are propelling the global cancer treatment market from $282 billion in 2025 toward $643.5 billion by 2034[3], creating powerful momentum for companies pioneering next-generation approaches including GT Biopharma, Inc. (NASDAQ:GTBP), Lexeo Therapeutics, Inc. (NASDAQ:LXEO), Anixa Biosciences, Inc. (NASDAQ:ANIX), Tempus AI, Inc. (NASDAQ:TEM)

Exclusive relationship through Named Patient Programs establishes footprint in Greece, Cyprus and additional Balkan countries CRANFORD, N.J., Oct. 7, 2025 /PRNewswire/ -- Citius Oncology, Inc. ("Citius Oncology" or the "Company") (NASDAQ:CTOR), a specialty biopharmaceutical company focused on the development and commercialization of novel targeted oncology therapies today announced it is actively engaging with regional distribution partners to make LYMPHIR™ (denileukin diftitox-cxdl) available to eligible patients through country-specific Named Patient Programs (NPPs) in Europe, South America and the Middle East. As part of its NPP strategy, Citius has entered into an exclusive distribution

Equity Insider News CommentaryIssued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, July 8, 2025 /PRNewswire/ -- Equity Insider News Commentary – As cancer rates climb and drug costs continue to soar, pressure is mounting on the private sector to drive innovation. Now, cancer experts are alarmed over a "gut wrenching" plan from the U.S. government to cut nearly 40% of National Cancer Institute funding, even as the price of oncology treatments pushes new limits—raising urgent concerns about access and affordability. In this shifting landscape, investors are turning their attention to a new wave of biotechs and specialty care providers developing breakthrough therapies and smarter care mo

USA News Group News CommentaryIssued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, June 26, 2025 /PRNewswire/ -- USA News Group News Commentary – With analysts forecasting the global oncology drug market to surpass US$900 billion by 2034, investor interest in cancer-focused biotechs is rapidly intensifying. ResearchAndMarkets and Vision Research Reports both point to strong double-digit growth, citing surging demand for next-gen diagnostics and immunotherapies. Yet even as market potential grows, the U.S. public health sector is facing potential setbacks. Budget proposals suggest National Cancer Institute (NCI) funding could be slashed by up to 40%, while Bloomberg highlights concerns 

USA News Group News Commentary Issued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, June 12, 2025 /PRNewswire/ -- After the close of the world's largest cancer conference (the 2025 American Society of Clinical Oncology annual meeting), doctors, scientists, and researchers are optimistic, especially in the fields of immunotherapy, Car T-cell therapy, liquid biopsies, breast cancer, AI, and even exercise. However, with reports coming out that the current US administration could drastically reduce funding of the National Cancer Institute (NCI) by nearly 40%, the market is looking towards the private sector to pick up the slack and continue to make advancements in cancer treatment. For inv

Clinical and regulatory success in 2024 expected to drive value in 2025 CRANFORD, N.J., Dec. 27, 2024 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius Pharma" or the "Company") (NASDAQ:CTXR), a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products today reported business and financial results for the fiscal full year ended September 30, 2024. Fiscal Full Year 2024 Business Highlights and Subsequent Developments Achieved U.S. Food and Drug Administration (FDA) approval of LYMPHIR™ (denileukin diftitox-cxdl), an immunotherapy for the treatment of adults with relapsed or refractory cutaneous T-cell lymphoma (CTCL);Advanced ma

SC 13G/A - CITIUS ONCOLOGY, INC. (0001851484) (Subject)

SC 13G/A - CITIUS ONCOLOGY, INC. (0001851484) (Subject)

SC 13D - CITIUS ONCOLOGY, INC. (0001851484) (Subject)